<DOC>
	<DOCNO>NCT02576938</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness baricitinib eczema .</brief_summary>
	<brief_title>A Study Baricitinib ( LY3009104 ) Participants With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Have moderatetosevere Atopic Dermatitis ( AD ) , determine follow : 1 . EASI 12 2 . Greater equal 10 % body surface area involvement 3 . Diagnosed AD least 2 year prior Have history inadequate clinical response eczema treatment Females pregnant nursing Participants agree use adequate contraception Are currently experience history : Skin condition psoriasis lupus erythematosus Skin disease require frequent hospitalization intravenous treatment Compromised immunity Serious illness could interfere study participation , clinically important deviation physical examination , vital sign measurement , electrocardiogram , abnormality laboratory test Currently experience history : Active latent Tuberculosis specific immunity disorder infection Malignancy lymphoproliferative disease last 5 year ( cervical , basal squamous skin cancer reoccurrence last 3 year ) Human Immunodeficiency Virus ( HIV ) Hepatitis B , Hepatitis C , chronic liver disease Have receive certain type vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atopic Eczema</keyword>
</DOC>